Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
OB

NASDAQ · OBIO

Orchestra BioMed Holdings, Inc.

Healthcare · Biotechnology

$6.12

Up+$0.31 (+5.34%)

Updated Sep 12, 2026, 8:07 AM

SID Score

6.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
257.76M
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$2.20 – $6.08
Volume
464.46K
Avg. volume
309.78K

Price performance

OBIO price history

1M range · 20 trading sessions · Daily adjusted prices

OBIO closed at $6.12 after 20 trading sessions, up 38.78% for the selected period.

Last close
$6.12
Period change
+38.78%
Period low
$4.41
Period high
$6.12
Daily close
View OHLC price history
OBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$5.87$6.25$5.7604$6.12464.46K
Sep 10, 2026$5.845$6.08$5.68$5.81761.62K
Sep 9, 2026$5.31$5.4599$5.2609$5.45198.56K
Sep 8, 2026$5.18$5.51$4.80$5.43359.34K
Sep 4, 2026$4.71$5.14$4.71$5.08478.14K
Sep 3, 2026$4.97$4.97$4.71$4.74325.59K
Sep 2, 2026$4.92$5.01$4.83$4.95240.38K
Sep 1, 2026$5.02$5.3492$4.875$4.90214.52K
Aug 31, 2026$5.23$5.33$5.0037$5.04276.55K
Aug 28, 2026$5.23$5.23$5.06$5.185154.46K
Aug 27, 2026$5.23$5.4199$5.10$5.11220.53K
Aug 26, 2026$5.36$5.45$5.16$5.26391.71K
Aug 25, 2026$5.37$5.50$5.35$5.36169.6K
Aug 24, 2026$5.35$5.48$5.21$5.44249.53K
Aug 21, 2026$5.45$5.53$5.27$5.36276.67K
Aug 20, 2026$5.53$5.58$5.38$5.43209.56K
Aug 19, 2026$5.492$5.78$5.49$5.55463.86K
Aug 18, 2026$4.74$5.77$4.69$5.662.06M
Aug 17, 2026$4.41$4.72$4.36$4.72221.59K
Aug 14, 2026$4.47$4.47$4.29$4.41142.77K

Latest OBIO news

The latest Smart Investors Daily articles mentioning OBIO.

Stock researchCompany · Overview

OBIO research

Overview

Company profile and research snapshot.

Company profile

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
13
OBIO recent ratings
DateFirmRatingTarget
Aug 11, 2026Piper SandlerOverweight—
May 19, 2026B. Riley SecuritiesBuy—
May 14, 2026HC Wainwright & Co.Buy—
May 13, 2026BarclaysOverweight—
Mar 12, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day. About Orchestra B

Yahoo · Aug 20, 2026

Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference

NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host one-on-one meetings with investors that day and on Wednesday, Sept. 9. A li

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By